Doxorubicin News and Research

RSS

Doxorubicin hydrochloride is approved for use with other drugs as adjuvant therapy for breast cancer that has spread to the lymph nodes, including cancer that is HER-2 positive or has spread after surgery.

In addition to the uses that have been approved by the FDA, doxorubicin hydrochloride is sometimes used alone or with other drugs to treat other types of cancer. The drug continues to be studied in the treatment of many types of cancer.

New treatment advances for patients with follicular lymphoma

A newly published study recommends that doctors carefully choose their patients' initial therapies because there are significant differences in overall survival rates, according to researchers at the University of Rochester Medical Center's James P. Wilmot Cancer Center.

20 Oct 2005

Rev/Dex combo looks like a breakthrough treatment for multiple myeloma

Mayo Clinic Cancer Center investigators report that combination therapy with lenalidomide (Revlimid) and dexamethasone (combination is called Rev/Dex) looks like a breakthrough treatment for multiple myeloma. Results of a Phase II clinical trial were published online Aug. 23 in Blood.

1 Sep 2005

Complex chemotherapy cocktails offers pluses, minuses in advanced endometrial cancer

Complex chemotherapy cocktails offer about one extra month of life to patients with end-stage endometrial cancer but also can result in severe, possibly fatal, side effects, according to the first systematic review of studies addressing the topic.

1 Sep 2005

Bone marrow may be source of new egg-cell generation

Last year a group of Massachusetts General Hospital (MGH) researchers announced surprising findings that female mice - contrary to longstanding theories of mammalian reproductive physiology - retained the ability to make new egg cells or oocytes into adulthood.

27 Jul 2005

Designed drug for combined hormone and chemotherapy treatment

The search for new drugs to fight cancer remains at the top of the to do list for pharmaceutical researchers. A recent variation is polymer chemotherapy agents, drugs that have been attached to a "backbone" of long chain molecules.

9 Jun 2005

Chemo combo increases breast cancer survival

A new Spanish study has found that a combination of chemotherapy drugs can increase the five-year survival rate of women with metastatic, node-positive breast cancer by 7 percent.

2 Jun 2005

Breast cancer chemotherapy regimen associated with life-threatening complications

The chemotherapy regimen of doxorubicin plus docetaxel, used to treat breast cancer in a clinical trial, was associated with an increased risk of serious complications, resulting in the premature termination of the trial, according to a study in the May 18 issue of JAMA.

17 May 2005

Doxorubicin-docetaxel combination is associated with an increased risk of severe and life-threatening complications

Researchers in France say a study using two chemotherapy agents to treat breast cancer was halted after two women in the study died.

17 May 2005

Taxotere shows significant survival benefit in the treatment of advanced gastric cancer

Final results from the largest international study in the treatment of advanced stomach cancer, also known as gastric cancer, demonstrated that patients who received a Taxotere (docetaxel) Injection Concentrate-based chemotherapy regimen (Taxotere, cisplatin and 5-fluorouracil) had significantly improved overall survival rates compared to patients who received a standard treatment (cisplatin and 5- fluorouracil).

16 May 2005

Sildenafil prevents anti-cancer drug induced heart damage

Virginia Commonwealth University researchers have found that the popular impotence drug Viagra prevents damage to the heart from a potent chemotherapeutic agent frequently used in the treatment of breast cancer, leukemia and sarcomas.

5 Apr 2005

Herceptin - more powerful treatment for patients with HER-2-positive breast cancer

A new use of the drug Herceptin appears to offer a much more powerful treatment advantage than expected for patients with HER-2-positive breast cancer, say researchers at The University of Texas M. D. Anderson Cancer Center.

29 Mar 2005

Smart nanocarrier technology will cancer treatment

A ‘smart’ nanocarrier technology developed by a team of researchers at the Institute of Bioengineering and Nanotechnology (IBN) is set to vastly improve the way cancer patients are treated.

22 Mar 2005

Study focuses on best treatment for older women with receptor negative early breast cancer

Older women with hormone receptor negative early breast cancer who may currently be missing out on effective post-operative anticancer drugs will be able to participate in a new clinical trial specifically aimed at this group of women.

27 Jan 2005

Researchers step closer to cure for common childhood cancer

Acute lymphoblastic leukemia (ALL) is a malignant disease caused by the abnormal growth and development of white blood cells (WBC) in the bone marrow and blood. ALL is the most common cancer occurring in children with an annual rate of approximately 30 to 40 new cases per million.

5 Dec 2004

Genetic predictions may bring “quantum leap” in breast cancer treatment success

Researchers at Virginia Commonwealth University’s Massey Cancer Center received a prestigious award and a $600,000 grant from the V Foundation for Cancer Research, one of the nation’s leading organizations devoted exclusively to funding cancer research.

20 Oct 2004

Cell Therapeutics receives Fast Track Designation for Pixantrone, treatment for aggressive non-Hodgkin's lymphoma

Cell Therapeutics, Inc. has received fast track designation from the U.S. Food and Drug Administration (FDA) for pixantrone, a novel anthracenedione, being investigated for the potential treatment of relapsed, aggressive non-Hodgkin's lymphoma (NHL).

12 Jul 2004

Dexrazoxane reduces heart damage caused by childhood leukemia treatment with doxorubicin (Adriamycin)

A potent chemotherapy that is highly effective in treating the most common form of childhood leukemia can significantly harm the heart, but findings from a multi-center study

9 Jul 2004